Cover Image
市場調查報告書

冠狀動脈支架市場分析:各產品(傳統金屬支架,藥劑溶出性血管支架,生物吸收性血管支架),及市場區隔預測

Coronary Stent Market Analysis by Product (Bare Metal Stents, Drug-Eluting Stents, Bioresorbable Vascular Scaffold) and Segment Forecasts to 2024

出版商 Grand View Research, Inc. 商品編碼 374559
出版日期 內容資訊 英文 74 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
冠狀動脈支架市場分析:各產品(傳統金屬支架,藥劑溶出性血管支架,生物吸收性血管支架),及市場區隔預測 Coronary Stent Market Analysis by Product (Bare Metal Stents, Drug-Eluting Stents, Bioresorbable Vascular Scaffold) and Segment Forecasts to 2024
出版日期: 2016年09月05日 內容資訊: 英文 74 Pages
簡介

本報告提供全球冠狀動脈支架市場相關調查,市場概要和今後預測,彙整各市場區隔及地區別趨勢,及加入此市場的主要企業簡介等資料。

第1章 調查方法

第2章 摘要整理

第3章 市場摘要

第4章 市場變動,趨勢,範圍

  • 市場區隔和範圍
  • 推動市場的要素分析
  • 阻礙市場的要素分析
  • 滲透及成長預測製圖
  • SWOT分析

第5章 市場類別1:產品預測及趨勢分析

  • 產品趨勢分析及市場佔有率
  • 市場規模與預測,及趨勢分析
    • 傳統金屬支架
    • 藥劑溶出性血管支架
    • 生物吸收性血管支架

第6章 市場類別2:各地區預測及趨勢分析

  • 各地區趨勢分析與市場佔有率
  • 市場規模與預測及趨勢分析
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲

第7章 競爭環境

  • 策略性架構
  • 企業簡介
目錄
Product Code: GVR-1-68038-106-1

The coronary stent market is expected to reach USD 15.2 billion by 2024, according to the new report by Grand View Research, Inc. Increasing burden of cardiovascular diseases (CVDs), including coronary artery diseases, are anticipated to boost the usage of coronary stents.

According to the World Health Organization, CVDs contribute to the maximum number of deaths globally. In 2012, approximately 17.5 million deaths were reported from CVDs, representing 31% of the global death statistics. Of the 17.5 million deaths reported, 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.

Individuals above 60 years of age form the key target population for these products. This demographic is characterized with low immunity levels and is prone to chronic diseases, including CVDs, which thereby serves as a high impact rendering driver for the growth of this industry over the forecast period. As a result, the latest treatments available in cardiac care are expected to increase the life span of the elderly population subset.

The coronary stent market is driven by reimbursement coverage provided by the Center for Medicare & Medicaid Services and private payers. The coverage is availed under national coverage scheme, which covers the product as well as the surgical procedure. The providers require completing certain conditions for coverage-all facilities performing CAS procedures should be certified by CMS.

Further Key Findings From the Study Suggest:

The coronary stent market is segmented on the basis of products: Bare Metal Stents, Drug Eluting Stents (DES), and Bioresorbable Vascular Scaffold (BVS).

DES held a lucrative share in 2015, which includes biodegradable and nonbiodegradable stents. Associated benefits such as avoidance of complications, ease of procedures, and comfort to the patient are responsible for the increased usage rates.

BVS is anticipated to be on forefront over the forecast period. With launch of first ever BVS in 2016, these products are likely to grow swiftly over the forecast period. BVS has added advantages of restoring vasomotor function, expanding future treatment options, and helping avoid future complications from occurring in permanent devices.

North America, especially the U.S., with its sophisticated healthcare system, well-planned reimbursement program, high healthcare expenditure, and large pool of target population held a substantial share in global coronary stents market.

Asia Pacific is anticipated to exhibit lucrative growth over the forecast period. Economic developments and government reforms, especially in countries like India and China, are supporting growth of this region. For instance, in India, the introduction of Goods and Services Tax (GST), a comprehensive tax system that avoids cascading tax effects, is helping both consumers and manufacturers save tax. This is anticipated to improve ease of doing business. Such initiatives open investment opportunities for market players in this region.

Some key players in the market include Abbott; Boston Scientific Corporation; Medtronic; B. Braun Melsungen AG; Terumo Corporation; Biotronik SE & Co. KG: Stentys SA; MicroPort Scientific Corporation; C. R. Bard, Inc.; and Cook Medical.

The market is oligopolistic in nature with few players at the top having similar share. However, recent activities by leading market players are opening avenues for emerging players in this vertical. For instance, loss of market share by Johnson and Johnson's product "Cypher" and discontinuation of its drug-eluting stent "Nevo" helped other players increase market penetration.

Table of Content

Chapter 1: Research Methodology

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2: Executive Summary

Chapter 3: Market Summary

Chapter 4: Market Variables, Trends & Scope

  • 4.1. Market Segmentation & Scope
  • 4.2. Market Driver Analysis
  • 4.3. Market Restraint Analysis
  • 4.4. Penetration & Growth Prospect Mapping
  • 4.5. SWOT Analysis, By Factor
    • 4.5.1. Political
    • 4.5.2. Economic
    • 4.5.3. Technology

Chapter 5: Market Categorization 1: Product Estimates & Trend Analysis

  • 5.1. Product Movement Analysis & Market Share, 2015 & 2024
  • 5.2. Market Size & Forecasts and Trend Analyses, 2013 to 2024 For the Following Products:
    • 5.2.1. Bare metal stents
    • 5.2.2. Drug-eluting stents
      • 5.2.2.1. Biodegradable
      • 5.2.2.2. Non-biodegradable
    • 5.2.3. Bioresorbable vascular scaffold

Chapter 6: Market Categorization 2: Regional Estimates & Trend Analysis

  • 6.1. Regional Movement Analysis & Market Share, 2015 & 2024
  • 6.2. Market Size & Forecasts and Trend Analyses, 2013 to 2024 for the following regions:
    • 6.2.1. North America
      • 6.2.1.1. U.S.
      • 6.2.1.2. Canada
    • 6.2.2. Europe
      • 6.2.2.1. UK
      • 6.2.2.2. Germany
    • 6.2.3. Asia Pacific
      • 6.2.3.1. Japan
      • 6.2.3.2. China
    • 6.2.4. Latin America
      • 6.2.4.1. Brazil
      • 6.2.4.2. Mexico
    • 6.2.5. MEA
      • 6.2.5.1. South Africa

Chapter 7: Competitive Landscape

  • 7.1. Strategy Framework
  • 7.2. Company Profiles
    • 7.2.1. Abbott
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Boston Scientific Corportaion
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Medtronic
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Terumo Corporation
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. B. Braun Melsungen AG
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Biotronik SE & Co. KG
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Stentys SA
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. MicroPort Scientific Corporation
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. C. R. Bard, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Cook Medical
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • TABLE 1: North America coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 2: North America drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 3: U.S. coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 4: U.S. drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 5: Canada coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 6: Canada drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 7: Europe coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 8: Europe drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 9: UK coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 10: UK drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 11: Germany coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 12: Germany drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 13: Asia Pacific coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 14: Asia Pacific drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 15: China coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 16: China drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 17: Japan coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 18: Japan drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 19: Latin America coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 20: Latin America drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 21: Brazil coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 22: Brazil drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 23: Mexico coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 24: Mexico drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 25: MEA coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 26: MEA drug eluting stents market, by product, 2013 - 2024 (USD Million)
  • TABLE 27: South Africa America coronary stent market, by product, 2013 - 2024 (USD Million)
  • TABLE 28: South Africa drug eluting stents market, by product, 2013 - 2024 (USD Million)

List of Figures

  • FIG. 1: Market summary
  • FIG. 2: Market trends & outlook
  • FIG. 3: Market segmentation & scope
  • FIG. 4: Market driver relevance analysis (Current & future impact)
  • FIG. 5: Market restraint relevance analysis (Current & future impact)
  • FIG. 6: Penetration & growth prospect mapping
  • FIG. 7: SWOT Analysis, by factor (Political & legal, economic and technological)
  • FIG. 8: Porter's Five Forces Analysis
  • FIG. 9: Coronary stent market product outlook: Key takeaways
  • FIG. 10: Coronary stents : Product movement analysis
  • FIG. 11: Bare metal stents market, 2013 - 2024 (USD Million)
  • FIG. 12: Drug eluting stents market, 2013 - 2024 (USD Million)
  • FIG. 13: Biodegradable drug eluting stents market, 2013 - 2024 (USD Million)
  • FIG. 14: Non-biodegradable drug eluting stents market, 2013 - 2024 (USD Million)
  • FIG. 15: Bioresorbable vascular sacaffold market, 2013 - 2024 (USD Million)
  • FIG. 16: North America coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 17: U.S. coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 18: Canada coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 19: Europe coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 20: UK coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 21: Germany coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 22: Asia Pacific coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 23: Japan coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 24: China coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 25: Latin America coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 26: Brazil coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 27: Mexico coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 28: MEA coronary stent market, 2013 - 2024 (USD Million)
  • FIG. 29: Saudi Arabia coronary stent market, 2013 - 2024 (USD Million)
Back to Top